Molecular Targeting Technologies Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
4
Molecular Targeting Technologies General Information
Description
Operator of a biotechnology company intended to develop novel radiopharmaceuticals for disease treatment and diagnosis. The company's technology focuses on radiolabeling the targeting molecule that assists in the early detection of tumor response to chemotherapy, cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome, and transplant rejection, enabling medical researchers to help in drug development and reduce patient treatment time with proper diagnoses.
Contact Information
Website
www.mtarget.comCorporate Office
- 833 Lincoln Avenue
- Unit 9
- West Chester, PA 19380
- United States
Corporate Office
- 833 Lincoln Avenue
- Unit 9
- West Chester, PA 19380
- United States
Molecular Targeting Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Grant | 01-Feb-2019 | Completed | Generating Revenue | |||
| 3. Grant | 09-Apr-2018 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2018 | $8.45M | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-Jan-2011 | Completed | Startup |
Molecular Targeting Technologies Patents
Molecular Targeting Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4196173-A1 | Compounds and compositions for tumor detection and surgical guidance | Pending | 14-Aug-2020 | ||
| EP-4196173-A4 | Compounds and compositions for tumor detection and surgical guidance | Pending | 14-Aug-2020 | ||
| EP-4013396-A1 | Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes | Inactive | 15-Aug-2019 | ||
| EP-4013396-A4 | Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes | Inactive | 15-Aug-2019 | ||
| US-11090309-B2 | Anti-thrombotic agents and methods of use thereof | Active | 30-Jun-2017 | A61K31/555 |
Molecular Targeting Technologies Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of Agriculture | Government | |||
| U.S. Department of Health and Human Services | Government | |||
| University of Notre Dame | University | |||
| Jefferson Accelerator Zone | Accelerator/Incubator |
Molecular Targeting Technologies FAQs
-
When was Molecular Targeting Technologies founded?
Molecular Targeting Technologies was founded in 2011.
-
Where is Molecular Targeting Technologies headquartered?
Molecular Targeting Technologies is headquartered in West Chester, PA.
-
What industry is Molecular Targeting Technologies in?
Molecular Targeting Technologies’s primary industry is Biotechnology.
-
Is Molecular Targeting Technologies a private or public company?
Molecular Targeting Technologies is a Private company.
-
What is Molecular Targeting Technologies’s current revenue?
The current revenue for Molecular Targeting Technologies is .
-
Who are Molecular Targeting Technologies’s investors?
United States Department of Agriculture, U.S. Department of Health and Human Services, University of Notre Dame, and Jefferson Accelerator Zone have invested in Molecular Targeting Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process